ERBB2 and breast cancer: To assess the polymorphism of PD-1, PD-L1, and PD-L2 and their correlation to breast cancer subtype, primary tumour samples were obtained from breast cancer patients, and tumours were defined into subtypes based on the expression of clinically used markers ER, PR, and HER2; and stage I, II, and III.